



ASX Announcement | 7 November 2025 AdAlta Limited (ASX:1AD)

Withdrawal of Resolution from 2025 AGM

Resolution 6 relating to proposed share consolidation is withdrawn from 2025 AGM

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products advises that the Board has decided, following new guidance from its corporate advisors, to withdraw Resolution 6 (proposed 10 for 1 share consolidation) referred to in the Notice of Annual General Meeting (“Meeting”) released to the ASX on Friday, 24 October 2025.

The withdrawal of Resolution 6 will not affect the validity of the proxy form provided in connection with the AGM, nor any proxy already submitted in respect of the remaining items of business.

All other items of business included in the Notice of Meeting will be put to shareholders at the AGM, scheduled to be held on Wednesday, 26 November 2025 at Piper Alderman, Level 23, 459 Collins Street, Melbourne, 3000 and as a virtual meeting.

To view a summary and engage in discussion about this announcement visit AdAlta’s InvestorHub here: <https://investorhub.adalta.com.au/link/P3jvor>

This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham

CEO & Managing Director

P: +61 403 446 665

E: ir@adalta.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its ‘East to West’ strategy, the Company is integrating Asia’s prowess in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients. AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)

Follow us on [LinkedIn](#)

Follow us on [X \(formerly Twitter\)](#)